공시 • Mar 10
Telo Genomics Corp. announced that it has received CAD 1.385 million in funding On March 9, 2026, Telo Genomics Corp. closed the transaction. The company issued Debentures for gross proceeds of CAD 545,000 in its second and final tranche. The company raised a total of CAD 1,385,000 under the offering. The Debentures bear interest at a rate of 15% per annum, compounded quarterly, and will mature on December 15, 2026 (the “Maturity Date”). The principal amount of the Debentures may, at the holder's election, at any time before the Maturity Date, be converted into common share of the Company (each, a “Share”) at a conversion price of CAD 0.05 per Share. The Company has no right to prepay the Debentures prior to the Maturity Date. In connection with the sale of the Debentures, the Company issued to the purchasers one transferable detachable warrant (a “Warrant”) for every CAD of principal amount of the Debentures subscribed for. The Company issued an aggregate of 10,900,000 Warrants in connection with the Second Tranche. Each Warrant will be exercisable to acquire one Share at an exercise price of CAD per Share until March 6, 2027. In connection with the Second Tranche, the Company paid cash finder’s fees of CAD 50 and issued 679,000 finder’s warrants (each, a “Finder’s Warrant”). Each Finder’s Warrant will be exercisable to acquire one Share at an exercise price of CAD per Share until March 6, 2028. The Debentures, Warrants and Finder’s Warrants issued in connection with the Second Tranche and any securities issuable upon conversion or exercise will be subject to a four month and one day hold period, expiring July 7, 2026 in accordance with applicable Canadian securities laws. The company announced that two subscribers who purchased an aggregate of CAD 00 of Debentures under the Second Tranche are considered to be related parties of the Company (the "Related Party Participation"). Specifically, John Price, the CFO of the Company, subscribed for CAD 00 of Debentures and 200,000 Warrants, and John Farlinger, a director of the Company, subscribed for CAD 35,000 of Debentures and 700,000 Warrants. 공시 • Jan 30
Telo Genomics Corp. Announces Chief Financial Officer Changes Telo Genomics Corp. announced that John Price has been appointed as Chief Financial Officer, effective January 30, 2026. John Price has over three decades of experience in accounting operations, financial planning, mergers and acquisitions, and capital markets. His prior experience includes executive positions in several public companies including Assure Holdings, National Beverage, Alliance MMA, and MusclePharm. He also held various accounting and finance roles in high growth technology companies in Silicon Valley including Opera Software, GCT Semiconductor and Tessera Technologies. John Price spent the first seven years of his career with Ernst & Young. He earned a Bachelor of Science in Accounting from Pennsylvania State University. John Price succeeds Christopher Ross who has served as the Company's CFO since April 2021. 공시 • Jan 19
Telo Genomics Corp. announced that it expects to receive CAD 1.2 million in funding Telo Genomics Corp announced a non-brokered private placement to issue secured convertible debentures for aggregate gross proceeds of CAD 1,200,000 on January 19, 2026. The Debentures will bear interest at a rate of 15% per annum, compounded quarterly, and will mature 9 months after the closing date. The principal amount of the Debentures may, at the holder's election, at any time before the Maturity Date, be converted into common shares of the Company at a conversion price of CAD 0.05 per common share. For every CAD 100,000 of convertible debentures issued, Telo Genomics will issue 2 million Detachable Warrants. Each Warrant will be exercisable to acquire one common share at an exercise price of CAD 0.08 per share for a period of 12 months from the closing date. The Company has no right to prepay the Debentures prior to the Maturity Date. The Debentures, Warrants and any securities issuable upon conversion or exercise will be subject to a four month hold period in accordance with applicable Canadian securities laws. 공시 • Oct 08
Telo Genomics Corp., Annual General Meeting, Dec 10, 2025 Telo Genomics Corp., Annual General Meeting, Dec 10, 2025. Location: ontario, toronto Canada 공시 • Jun 20
Telo Genomics Corp. Initiate Clinical Trial Forimal Residual Disease in Multiple Myeloma Telo Genomics Corp. announced that it has initiated a multiple myeloma ("MM") clinical trial in collaboration with Cleveland Clinic Cancer Institute, Cleveland, OH. The samples are to be assessed and stratified between minimal residual disease ("MRD") patients that are active or in remission, in a clinical trial of the Company's TeloView MM-MRD assay. Telo Genomics announced its initial MRD trial in MM on February 22, 2024, in collaboration with McGill University/Jewish General Hospital, Montreal, Canada (NCT05530096). The new collaboration with Cleveland Clinic allows Telo to expand access and recruitment from a broader spectrum of patient groups, including patients receiving new CAR-T therapies that are more prevalent in the USA, and can contribute to expediting the validation of TeloViewMM-MRD.MRD refers to the small number of remaining cancer cells post treatment. The TeloView MM-MR D test provides industry leading sensitivity for counting MRD cells, which is an established metric in assessing MRD. Critically, the TeloView MM-MRd test also offers the potential to profile the malignancy of individual cancer cells and stratify patients based on the aggressiveness of their remaining MRD. TeloView MM-MRB's proprietary approach of counting and profiling individual MRD cells has the potential to provide important, actionable information to clinicians and provide guidance in decision making, including; the extension of therapy, stopping therapy or resuming therapy, with the potential to improve clinical outcomes for MM patients post treatment. In North America, there are approximately 180,000 MM patients receiving treatment across the spectrum of different stages of the disease. Most of these patients could benefit from ongoing monitoring of treatment response using MRD assessment. Depending on the stage of the disease, patients may be monitored on a quarterly basis, leading to a total addressable market of approximately 800,000 tests per year. While the initial focus is on MM MRD, the collaboration allows for additional research that can validate assays for other utility cases in hematological malignancies, such as TeloView SMM, which is an assay that stratifies patients that are identified as having smoldering MM, a precursor to active MM. About MRD Assessment. MRD is defined as the small number of cancer cells that remain in the body after treatment, stratifying MRD cells as in remission or active provides important actionable information for clinicians. Also, the FDA's Oncologic Drugs Advisory Committee (ODAC) voted unanimously in April 2024 to accept MRD as a clinical endpoint for accelerated approval of new multiple myeloma therapies, paving the way for faster drug approvals. Minimal residual disease (MRD) testing is emerging as an important tool in assessing treatment response and guiding therapeutic decisions in oncology. With advancements in drug development technologies, and a growing emphasis on personalized healthcare, the MRD testing industry is expected to exhibit substantial global expansion in the coming years. The MRD global testing market size is. expected to reach USD 4.1 billion by 2032 (Globe Newswire - August 14, 2023). About Multiple Myeloma. MRD treatment includes various combinations of drugs with a cost as high as $150,000 per year per patient. As most patients will develop resistance to treatment and relapse within a median of 2 years, identifying them proactively remains another important clinical need. Notably, the total addressable market for both MM assays is over 750,000 tests per year in the US. 